Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Valuable Targets
6 min read
Analysis on the Research Progress of D2 Receptor Agonist
8 November 2023
The D2 receptor is a type of dopamine receptor found in the human body. It plays a crucial role in various physiological and neurological processes.
Drug Insights
4 min read
A Comprehensive Review of Melarsoprol's R&D Innovations and Drug Target Mechanism
8 November 2023
This article summarized the latest R&D progress of Melarsoprol, the Mechanism of Action for Melarsoprol, and the drug target R&D trends for Melarsoprol.
Latest Hotspot
4 min read
2023 AAO | Innovent Biologics Announces Latest Clinical Data for Dual-Target Ophthalmic New Drugs IBI302 and IBI324
8 November 2023
Innovent Biologics reported two clinical research outcomes at the 2023 AAO annual meeting on Nov 6, 2023. These include the Phase 2 clinical data for IBI302, an anti-VEGF-anti-complement dual target drug for nAMD treatment, and Phase 1 clinical data for IBI324, an anti-VEGF-A/Ang-2 bispecific antibody for DME treatment.
Drug Insights
4 min read
Pharmaceutical Insights: Menotropins's R&D Progress and its Mechanism of Action on Drug Target
8 November 2023
This article summarized the latest R&D progress of Menotropins, the Mechanism of Action for Menotropins, and the drug target R&D trends for Menotropins.
Bio Sequence
2 min read
Biological Glossary | What is Linker?
8 November 2023
In biology, linkers refer to short amino acid sequences found in nature that separate multiple domains in a single protein.
Latest Hotspot
3 min read
The phase 2 clinical trial of Otsuka/Visterra's anti-APRIL monoclonal antibody, sibeprenlimab, for the treatment of IgA nephropathy is published in the NEJM
8 November 2023
Otsuka Pharmaceutical and Visterra recently reported that the full Phase II trial results for sibeprenlimab (VIS649), a treatment for IgA nephropathy, have been published in the NEJM.
Drug Insights
4 min read
Exploring Metadoxine's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
8 November 2023
This article summarized the latest R&D progress of Metadoxine, the Mechanism of Action for Metadoxine, and the drug target R&D trends for Metadoxine.
Latest Hotspot
3 min read
The first participant has been administered HG004 in an international phase 1/2 study against hereditary blindness, as disclosed by Huidagene Therapeutics
8 November 2023
HuidaGene Therapeutics, a global oncology-focused biotech company, has announced its first treatment in its multinational HG004 gene therapy study (STAR study). This phase 1/2a investigation uses CRISPR-influenced programmable genomic drugs to potentially treat inherited retinal dystrophies caused by RPE65 gene mutations.
Bio Sequence
2 min read
Biological Glossary | What is Intron?
8 November 2023
An intron, derived from the term "intragenic region", is a nucleotide sequence within a gene that does not directly code for proteins and does not remain in the final mature mRNA molecule following the gene's transcription.
Drug Insights
4 min read
Decoding Metyrosine: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
8 November 2023
This article summarized the latest R&D progress of Metyrosine, the Mechanism of Action for Metyrosine, and the drug target R&D trends for Metyrosine.
Latest Hotspot
3 min read
The FDA gives the go-ahead to Novartis Cosentyx® - a first biological treatment innovation for hidradenitis suppurativa sufferers in roughly ten years
7 November 2023
Novartis reported FDA's approval of Cosentyx® (secukinumab) for the management of moderate to extreme hidradenitis suppurativa in adult patients.
Drug Insights
4 min read
Deep Scientific Insights on Mexazolam's R&D Progress, Mechanism of Action, and Drug Target
7 November 2023
This article summarized the latest R&D progress of Mexazolam, the mechanism of action for Mexazolam, and the drug target R&D trends for Mexazolam.